T-cell Engaging bispecific antibodies (TCEs) are promising off-the-shelf T cell engaging therapies, that redirect T cells towards tumor cells in a TCR/MHC-independent fashion. CD20-TCE, particularly, is emerging as a major therapeutic option for B cell lymphoma patients. Understanding the determinants of T cell cytotoxicity is essential, yet fundamental studies on TCEs have been singularly limited by the absence of homology between human and murine CD3e, the molecular target of TCE on T cells.
Here, we establish an immunocompetent mouse model, that allows thorough characterization of CD20-TCE’s mode of action in vivo. We aim to delineate how the T cell landscape and the rest of the immune compartments are modified by TCE injection in vivo, at different timepoints.
